Gunhild M. Mælandsmo is the head of Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital where she also is heading the “Metastasis Biology and Experimental Therapeutics” research group. She is a Professor at Faculty of Health Sciences, University of Tromsø.
Mælandsmo emphasizes translational research and the group utilizes patient tumor samples for molecular characterization and for functional investigations in patient-derived model systems. To combat metastatic cancer, our objective is to understand the underlying biological mechanisms causing therapy resistance, invasion and re-growth. The goal is to identify factors that can be utilized as prognostic and predictive biomarkers, or as targets for therapy. We are working with melanoma, breast cancer and prostate cancer.
Mælandsmo is the PI for the MetAction project – Actionable Targets in Cancer Metastasis – including the first Norwegian clinical trial in precision oncology where treatment decisions in metastatic patients has been based on data from targeted Next Generation Sequencing.